<DOC>
	<DOCNO>NCT01953705</DOCNO>
	<brief_summary>Brain scan help identify change appear increase risk cognitive decline dementia . Some brain change think reflect actual damage small blood vessel support normal brain function . This clinical trial determine whether omega 3 polyunsaturated fatty acid ( PUFA ) therapy promote brain health support small blood vessel brain 3 year old adult high risk cognitive decline dementia Alzheimer 's type .</brief_summary>
	<brief_title>n-3 PUFA Vascular Cognitive Aging</brief_title>
	<detailed_description>The main objective study determine omega 3 PUFA slow accumulation brain MRI derive white matter hyper-intensities ( WMH ) 3 year population risk dementia . This trial design collect preliminary data mechanism PUFA therapy operate brain special attention vascular component . The randomized , double-blind control trial rigorously test PUFA effect versus placebo non-demented elder 3 year . This biomarker base trial enroll 150 elder . Aim 1 assess PUFA effect neuroimaging parameter change . Aim 2 assess PUFA effect blood-based biomarkers endothelial health , Aim 3 collect preliminary data PUFA effect neuropsychological functional parameter special attention executive speed process skill gait speed .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Dementia , Vascular</mesh_term>
	<criteria>1 . Nondemented mild cognitive impairment , define Clinical Dementia Rating =0 0.5 MMSE &gt; =24 . 2 . Age 75 old , male female 3 . Total WMH volume ≥ 5 cc 4 . Plasma PUFA index ( EPA + DHA ) &lt; 110 ug/ml &lt; 5.5 weight percent 5 . Sufficient English language skill complete test 6 . Geriatric Depression Scale 15 &lt; 6 document absence significant depressive syndrome 7 . Sufficient vision hear complete test 8 . Informant available frequent ( least 1 hour/day 1 day/week ) contact subject verify functional status CDR rating 9 . General health status interfere ability complete prospective study ( condition list study exclusion list ) 1 . Any dementing illness ( AD , vascular dementia , normal pressure hydrocephalus , Parkinson 's disease ) ; dementia define CDR ≥ 1 , MMSE &lt; 24 2 . Significant disease CNS brain tumor , seizure disorder , subdural hematoma , cranial arteritis 3 . Alcohol substance abuse accord DSMIV criterion within last 2 year 4 . Major depression , schizophrenia , major psychiatric disorder define DSMIV criterion 5 . Abnormal labs indicate vitamin B12 deficiency , thyroid disease , UTI ( document bacterial colonization acceptable ) 6 . Unstable significantly symptomatic CVD ( e.g . CAD frequent angina , CHF dyspnea rest ) 7 . Hypertension : define uncontrolled BP &gt; 150/90 8 . Clinical symptomatic orthostatic hypotension 9 . Diabetes mellitus require insulin injection 10 . History cortical stroke 11 . Cancer within last 5 year , exception localize prostate cancer ( Gleason Grade &lt; 3 ) nonmetastatic skin cancer ( melanoma ) . 12 . Illness require &gt; 1 visit /month clinician 13 . Contraindications MRI ( i.e. , heart pacemaker , metal plate object head , , claustrophobia ) 14 . Medications : 1 . CNS active med stable dos least 2 month ( cimetidine , betablockers , SSRIs ) 2 . Neuroleptics , antiparkinsonian agent , systemic corticosteroid , narcotic analgesic ; case use selflimited time must discount period five halflives prior baseline visit 3 . Over counter supplement exclusionary , however , subject ask change dose regimen course trial unless medically indicate ; presence dose agent record 4 . A baseline screen plasma PUFA &gt; 5.5 weight percent total fatty acid EPA+DHA confirm supplementation O3PUFA history . If patient indicate regular supplementation fish oil phone screen , wash 4 month prior study visit one . 5 . Cholinesterase inhibitor ( i.e. , Aricept ) 6 . Investigational drug within five halflives prior baseline 7 . Anticoagulation therapy : Vitamin K antagonist : warfarin ( Coumadin , jantoven ) , Factor Xa inhibitor : rivaroxaban ( xarelto ) , fondaparinux ( arixtra ) , dibigatran ( pradaxa ) , apixaban ( eliquis ) ; Low molecular weight heparin : dalteparin ( fragmin ) , enoxaparin ( lovenox ) ( Incident use anticoagulant therapy exclude study drug allocation . However , subject ask complete followup visit . )</criteria>
	<gender>All</gender>
	<minimum_age>75 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>omega 3 fatty acid</keyword>
	<keyword>cognitive decline</keyword>
	<keyword>MRI</keyword>
	<keyword>endothelial function</keyword>
	<keyword>white matter</keyword>
	<keyword>executive function</keyword>
	<keyword>prevention</keyword>
	<keyword>DTI</keyword>
	<keyword>ASL</keyword>
</DOC>